Form 4: Fulgent Genetics' President and COO, Jian Xie, Reports Changes in Beneficial Ownership

Jian Xie, President and COO of Fulgent Genetics, reports acquisition and disposal of common stock due to vesting of restricted stock units and tax withholding obligations.

Summary

• On February 25, 2025, Jian Xie, President and COO of Fulgent Genetics, acquired shares of common stock through the vesting of performance-based restricted stock units.
• These shares were granted on February 28, 2022 (3,384 shares), February 23, 2023 (5,480 shares), and February 26, 2024 (14,297 shares).
• Additionally, 45,304 shares vested as restricted stock units.
• Xie also disposed of shares to satisfy tax withholding obligations related to the vesting of these restricted stock units.
• Specifically, 1,823 shares, 2,951 shares, and 8,031 shares were withheld on February 25, 2025, at a price of $16.29 per share.
• On February 26, 2024, 4,551 shares were withheld at $16.24 per share.
• Following these transactions, Xie directly owns 384,889 shares of common stock and indirectly owns 220,816 shares through The Hsieh Family Dynasty Trust.
• The restricted stock units vest over three years, with the first tranche vesting on March 1, 2025, and subsequent tranches vesting quarterly thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. The vesting of performance-based units suggests the company is meeting its goals, but the subsequent sale for tax obligations is a neutral event.

Positives

• The vesting of restricted stock units indicates that performance milestones were likely met, suggesting positive performance for the company.
• The increase in direct ownership to 384,889 shares demonstrates a continued vested interest in the company's success by the President and COO.

Negatives

• The disposal of shares to cover tax obligations, while standard, slightly reduces the overall holdings of the reporting person.

Risks

• Future vesting events could lead to further sales of shares to cover tax obligations, potentially creating downward pressure on the stock price.
• The reliance on performance-based metrics for vesting could introduce volatility in ownership changes based on the company's ability to meet those targets.

Future Outlook

Remaining restricted stock units will continue to vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2025, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.

Management Comments

• Mr. Xie disclaims any beneficial interest in the shares held by The Hsieh Family Dynasty Trust except with respect to any pecuniary interest therein.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects. Vesting of restricted stock units is a common form of executive compensation in the biotech and genetics industry.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotech industry to align management's interests with those of shareholders.
• Companies like Illumina (ILMN) and Thermo Fisher Scientific (TMO) also utilize restricted stock units and performance-based equity awards as part of their executive compensation packages.
• The vesting schedules and performance metrics associated with these awards vary depending on the company's specific goals and objectives.
• The tax withholding practices observed in this filing are standard across publicly traded companies.

Stakeholder Impact

• Shareholders may view the vesting of performance-based units as a positive sign of company performance.
• Employees may be motivated by the potential for future equity awards and vesting opportunities.

Next Steps

• Continued monitoring of insider transactions to assess management's sentiment and potential impact on stock price.
• Tracking the vesting schedule of remaining restricted stock units.

Key Dates